Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Cancer Res. 2004 Mar 1;64(5):1595-9.

CD4(+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation.

Author information

  • 1Surgery Branch, National Cancer Institute, Center for Cancer Research, NIH, Bethesda, MD 20892, USA.


The potential of antigen-directed cancer immunotherapy has not been fully realized, perhaps because many commonly targeted tumor associated proteins are not essential to maintaining the malignant cell phenotype. A constitutively activating mutation in the signaling molecule BRAF is expressed frequently in melanomas and may play an important role in the biology of this disease. A 29-mer B-Raf peptide incorporating the V599E mutation was used for in vitro stimulation of lymphocytes derived from melanoma patients, generating MHC class II-restricted CD4(+) T cells specific for this peptide as well as for melanoma cells expressing B-Raf V599E. Mutated B-Raf exemplifies targets that may be ideal for immunotherapy.

[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk